August 3, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention:    Irene Paik

Re:	Nautilus Biotechnology, Inc.
	Registration Statement on Form S-1
	File No. 333-258100
	Acceleration Request
		Requested Date: August 6, 2021
		Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nautilus Biotechnology, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-258100) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Zachary B. Myers at (858) 350-2350.

Sincerely,

NAUTILUS BIOTECHNOLOGY, INC.

/s/ Sujal Patel

Sujal Patel

Chief Executive Officer

cc:	Anna Mowry
	Matthew Murphy
	Nautilus Biotechnology, Inc.
	Robert F. Kornegay
	Zachary B. Myers
	Wilson Sonsini Goodrich & Rosati, P.C.